Loading clinical trials...
Loading clinical trials...
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT04955210 · Critical Illness, Severe Sepsis
NCT06143137 · Severe Sepsis
NCT05296590 · Bacteremia, Bacteremia Sepsis, and more
NCT04027699 · Severe Sepsis or Septic Shock in Pediatric Intensive Care Unit
NCT02473263 · Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit
Uc Davis Medical Center
Sacramento, California
Univ. Of Colorado Health
Colorado Springs, Colorado
Denver Health Medical Center
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions